Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relugolix Duration in High Risk Prostate Cancer
NCT06129851Phase 2Not yet recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- Nov 2023
- Primary completion
- Oct 2025
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tissue-plasminogen activator in prostate cancer (PCa) (2 arms), sponsored by University of Kansas Medical Center. Primary endpoint: Biochemical recurrence rate at 3 years. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06129851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06129851.